A Grunenthal First: Establishing A US Presence With A Tailored Marketing Strategy

15 Nov 2018

• By John Davis

Germany's pain-focused specialty pharmaceutical firm is adding America to its commercial reach, through acquiring New York's Averitas Pharma to jumpstart its push to commercialize products on its own account, via a niche approach.

Broken arm — Complex regional pain syndromes often involve injured extremities. • Source: Shutterstock

By acquiring the small New York-based company, Averitas Pharma, the family-owned European-based specialty company, Grunenthal GMBH, is aiming to use Averitas's experience in a specialty pharmacy and hub services model to commercialize, for the first time, its own portfolio of niche pain-related therapies in the US.

The acquisition confirms that US market opportunities are as much a draw for privately held companies as they are for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.